NCT02812667View on ClinicalTrials.gov

Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 29, 2016

Primary Completion Date

November 24, 2024

Study Completion Date

October 24, 2025

Conditions
Non-small Cell Lung Cancer Metastatic
Interventions
DRUG

Nivolumab + Plinabulin

Trial Locations (1)

92093

UC San Diego Moores Cancer Center, La Jolla

Sponsors
All Listed Sponsors
collaborator

BeyondSpring Pharmaceuticals Inc.

INDUSTRY

lead

Lyudmila Bazhenova, M.D.

OTHER

NCT02812667 - Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter